# DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

> **NCT03523585** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 608 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Capecitabine
- **DRUG:** Lapatinib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT03523585
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2025-12-23
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523585, "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03523585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*